Related Experiment Video
Updated: Dec 27, 2025

Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Relationship between pancreatic cancer-associated diabetes and cachexia
Wei-Chih Liao1,2, Peng-Ruei Chen3, Cheng-Chieh Huang3
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Pancreatic cancer-associated diabetes mellitus (PCDM) does not directly cause cachexia. Biomarkers like galectin-3 and S100A9, and blood glucose levels, were not associated with weight loss or muscle loss in cancer patients.
Area of Science:
- Oncology
- Endocrinology
- Metabolic Syndrome
Background:
- Pancreatic cancer-associated diabetes mellitus (PCDM) is a paraneoplastic phenomenon linked to hyperglycemia and weight loss.
- Mediators of PCDM, such as galectin-3 and S100A9, possess pro-inflammatory properties that may contribute to systemic inflammation and cachexia.
- The direct role of PCDM in mediating cancer-induced cachexia remains unclear.
Purpose of the Study:
- To investigate whether pancreatic cancer-associated diabetes mellitus (PCDM) directly mediates cachexia in pancreatic cancer patients.
- To analyze the association between PCDM, hyperglycemia, and cachexia-related parameters, including weight loss and skeletal muscle index (SMI).
- To determine the correlation between serum levels of galectin-3 and S100A9 with cachexia in pancreatic cancer.
Main Methods:
- A comparative study included 88 pancreatic cancer (PC) patients with PCDM and 88 without.
- Cachexia was defined by weight loss, low body mass index, or sarcopenia. Skeletal muscle mass was assessed using CT-scans (SMI).
- Statistical analyses, including Spearman correlation and logistic regression, were used to compare cachexia parameters and analyze relationships with blood glucose and biomarker levels.
Main Results:
- Cachexia prevalence (64.8% vs. 51.1%), weight loss (median 6.8% vs. 4.0%), and SMI were not significantly different between patients with and without PCDM.
- In patients with PCDM, fasting blood glucose did not correlate with weight loss or SMI. Serum S100A9 correlated with fasting blood glucose but not with weight loss or SMI.
- Primary tumor size was associated with cachexia, but PCDM, fasting blood glucose, galectin-3, and S100A9 were not identified as predictors of cachexia.
Conclusions:
- Neither hyperglycemia nor serum levels of galectin-3 and S100A9 were associated with cachexia-related parameters in pancreatic cancer patients.
- The study concludes that mediators of PCDM and hyperglycemia do not directly mediate pancreatic cancer-induced cachexia.
- Primary tumor size is a significant predictor of cachexia, independent of PCDM status or associated biomarkers.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Acute Pancreatitis II: Clinical Manifestations and Management
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

